Dr. Sadettin Ozturk is the President and CEO of ArtiaBio Inc. He has had a long career in cell culture process development, technology transfer, product licensing, and commercial manufacturing. Sadettin led process development activities and played a key role in the licensing and commercialization of three monoclonal antibodies, Stelera®, Simponi®, and Sylant®. In addition, he transferred and supported the commercial manufacturing of Kogenate®, BeneFix®, and Remicade®.
His activities later expanded to the vaccine production and Cell and Gene Therapy a(CGT) applications for AAV and Lentivirus based vector manufacturing. Sadettin has published numerous research articles, given presentations, delivered keynote lectures, and edited books. Sadettin is involved in these scientific organizations and other community activities by serving on their Scientific Advisory Boards and organizing meetings and sessions. He has served Biochemical Technology (BIOT) division of American Chemical Society as the Division Chair, and then as a Councilor. He co-authored a well-respected book in the field entitled Cell Culture Technology for Pharmaceutical and Cellular Therapies. Sadettin also serves on Editorial and Review Boards for several journals and other publications.